Akili (AKLI) Interest Expense : $-2.36 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Akili Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Akili's interest expense for the three months ended in Dec. 2023 was $ -0.52 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.36 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Akili's Operating Income for the three months ended in Dec. 2023 was $ -11.62 Mil. Akili's Interest Expense for the three months ended in Dec. 2023 was $ -0.52 Mil. Akili did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Akili Interest Expense Historical Data

The historical data trend for Akili's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili Interest Expense Chart

Akili Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.16

-0.33

-0.47

-1.48

-2.36

Akili Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial								-0.62	-0.62	-0.64	-0.58	-0.52

Akili Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.36 Mil.

Akili (NAS:AKLI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Akili's Interest Expense for the three months ended in Dec. 2023 was $-0.52 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-11.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $7.23 Mil.

Akili's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Akili did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Akili (AKLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AKLI:Mexico

Address

125 Broad Street, Fifth Floor, Boston, MA, USA, 02110

Website

https://www.akiliinteractive.com

Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.

Executives

Jacqueline Studer	officer: Chief Legal Officer	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin	officer: See Remarks	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii	director, officer: Chief Executive Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag	officer: Chief Financial Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya	director, 10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges	director	C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina	officer: Chief Medical Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David	officer: Chief Product Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110